Subject Satisfaction with Trifarotene 50 μg/g Cream in the Treatment of Facial and Truncal Acne Vulgaris: A Case Series.
Acne
Case series
Facial
Retinoid
Trifarotene
Truncal
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
01
06
2020
pubmed:
6
7
2020
medline:
6
7
2020
entrez:
6
7
2020
Statut:
ppublish
Résumé
There is a paucity of literature covering patient-reported outcomes of treatments for truncal acne. Trifarotene 50 μg/g cream is a novel retinoid molecule approved for once-daily topical treatment of facial and truncal acne vulgaris. As physicians are starting to gain real-world experience with this retinoid treatment, their access to reporting from the patient's perspective provides a valuable adjunct to the pivotal studies. We report a case series of three subjects with moderate facial and truncal acne treated with trifarotene 50 μg/g cream on the face, shoulders, upper back and upper anterior chest for 12 weeks and evaluated by satisfaction questionnaires. This case series illustrating the treatment of facial and truncal acne with trifarotene 50 μg/g cream, in the form of real-world data, describes high overall satisfaction and excellent tolerability to support the use of this new retinoid molecule in the treatment of acne vulgaris on both the face and trunk.
Identifiants
pubmed: 32623660
doi: 10.1007/s13555-020-00417-4
pii: 10.1007/s13555-020-00417-4
pmc: PMC7477054
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1165-1173Références
Claudel JP, Auffret N, Leccia MT, Poli F, Dréno B. Acne from the young patient's perspective. J Eur Acad Dermatol Venereol. 2020;34(5):942–7.
doi: 10.1111/jdv.16067
Tan JK, Tang J, Fung K, et al. Prevalence and severity of facial and truncal acne in a referral cohort. J Drugs Dermatol. 2008;7(6):551–6.
pubmed: 18561586
Del Rosso JQ, Bikowski JB, Baum E, et al. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol. 2007;6(6):597–600.
pubmed: 17668525
Poli F, Auffret N, Leccia MT, Claudel JP, Dréno B. Truncal acne, what do we know? J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16634 .
doi: 10.1111/jdv.16634
pubmed: 32421879
Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are mainstay of therapy for acne. Dermatol Ther (Heidelb). 2017;7:293–304.
doi: 10.1007/s13555-017-0185-2
Thiboutot DM, Dréno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2 Suppl 1):S1–S23.
doi: 10.1016/j.jaad.2017.09.078
Kassir M, Karagaiah P, Sonthalia S, et al. Selective RAR agonists for acne vulgaris: a narrative review. J Cosmet Dermatol. 2020;19(6):1278–83.
doi: 10.1111/jocd.13340
Aubert J, Piwnica D, Bertino B, et al. Non-clinical and human pharmacology of the potent and selective topical RAR-γ agonist trifarotene. Br J Dermatol. 2018;179:442–56.
pubmed: 29974453
Thoreau E, Arlabosse J, Bouix-Peter C, et al. Structure-based design of Trifarotene (CD5789), a potent and selective RAR-γ agonist for the treatment of acne. Bioorg Med Chem Lett. 2018;28:1736–41.
doi: 10.1016/j.bmcl.2018.04.036
Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–9.
doi: 10.1016/j.jaad.2019.02.044
Wagner N, Benkali K, Alió Sáenz A, Poncet M, Graeber M. Clinical pharmacology and safety of trifarotene, a first-in-class RARγ-selective topical retinoid. J Clin Pharmacol. 2020;60(5):660–8.
pmcid: 7187247
Blume-Peytavi U, Fowler J, Kemény L, et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34(1):166–73.
doi: 10.1111/jdv.15794
US Food and Drug Administration. Summary of product characteristics. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf . Accessed 31 May 2020.
Myhill T, Coulson W, Nixon P, Royal S, McCormack T, Kerrouche N. Use of supplementary patient education material increases treatment adherence and satisfaction among acne patients receiving adapalene 0.1%/benzoyl peroxide 2.5% gel in primary care clinics: a multicenter, randomized controlled clinical study. Dermatol Ther (Heidelb). 2017;7(4):515–24.
doi: 10.1007/s13555-017-0203-4